Yonsei Med J.  2012 Sep;53(5):1045-1048.

Serum Amyloid A Circulating Levels and Disease Activity in Patients with Juvenile Idiopathic Arthritis

• Cantarini
• Giani T
• Fioravanti A
• Iacoponi F
• Simonini G
• Pagnini I
• Spreafico
• Chellini F
• Galeazzi M
• Cimaz R

Abstract

The aim of our study was to evaluate the association between circulating levels of serum amyloid A protein (SAA) and disease activity in patients with juvenile idiopathic arthritis (JIA). Our study group included 41 JIA patients (9 male, 32 female), classified according to the International League of Associations for Rheumatology (ILAR) criteria (5); 16 had polyarticular onset disease and 25 had oligoarticular onset disease. Among 25 patients with oligoarticular disease, three had extended oligoarthritis. Serum amyloid A (SAA), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured in both patients and 26 healthy controls. SAA levels were higher in JIA patients versus healthy controls (p<0.001). Significant positive correlations were found between SAA and the presence of active joints (rho=0.363, p<0.05), the number of active joints (rho=0.418, p<0.05), ESR (R=0.702, p<0.05) and CRP (R=0.827, p<0.05). No significant correlations between ESR and the presence of active joints (rho=0.221, p=0.225) or between ESR and the number of active joints (rho=0.118, p=0.520) were demonstrated in JIA patients. No significant correlations were obtained between CRP and the presence of active joints (rho=0.034, p=0.855) or between CRP and the number of active joints (rho=0.033, p=0.859). We discovered a significant increase in SAA levels in JIA patients, compared to controls, and a strong positive correlation between SAA level and JIA disease activity. We also discerned SAA to be a more sensitive laboratory marker than ESR and CRP for evaluating the presence and number of active joints. We suggest that SAA can be used as an additional indicator of disease activity in JIA.

Keyword

Serum amyloid A; juvenile idiopathic arthritis; inflammatory markers; disease activity

MeSH Terms

Arthritis, Juvenile*
Biomarkers
Blood Sedimentation
C-Reactive Protein
Humans
Joints
Male
Rheumatology
Serum Amyloid A Protein*
Biomarkers
C-Reactive Protein
Serum Amyloid A Protein

Figure

• 

  Fig. 1 Plots with regression lines between SAA and ESR (A) and CRP (B) variables. SAA, serum amyloid A; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

Reference

1. Husby G, Marhaug G, Dowtor B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid. 1994. 1:119–137.

2. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999. 265:501–523.

3. Jung SY, Park MC, Park YB, Lee SK. Serum amyloid A as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J. 2007. 48:218–224.

4. Lange U, Boss B, Teichmann J, Klör HU, Neeck G. Serum amyloid A--an indicator of inflammation in ankylosing spondylitis. Rheumatol Int. 2000. 19:119–122.

5. Cleary AG, Sills JA, Davidson JE. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 2000. 27:1568.

6. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res. 2000. 2:142–144.

7. Shimojima Y, Matsuda M, Gono T, Ishii W, Ikeda S. Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica. Intern Med. 2005. 44:1009–1012.

8. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009. 61:1484–1490.

9. Scheinberg MA, Hubscher O, Morteo OG, Benson MD. Serum amyloid protein levels in south american children with rheumatoid arthritis: a co-operative study. Ann Rheum Dis. 1980. 39:228–230.

10. Hachulla E, Saile R, Parra HJ, Hatron PY, Gosset D, Fruchart JC, et al. Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease. Clin Exp Rheumatol. 1991. 9:157–163.

11. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004. 314:363–369.

12. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999. 37:381–388.